BACKGROUND: Resistance to therapy with BRAF kinase inhibitors is associated with reactivation of the mitogen-activated protein kinase (MAPK) pathway. To address this problem, we conducted a phase 1 and 2 trial of combined treatment with dabrafenib, a selective BRAF inhibitor, and trametinib, a selective MAPK kinase (MEK) inhibitor. METHODS: In this open-label study involving 247 patients with metastatic melanoma and BRAF V600 mutations, we evaluated the pharmacokinetic activity and safety of oral dabrafenib (75 or 150 mg twice daily) and trametinib (1, 1.5, or 2 mg daily) in 85 patients and then randomly assigned 162 patients to receivecombination therapy with dabrafenib (150 mg) plus trametinib (1 or 2 mg) or dabrafenib monotherapy. The primary end points were the incidence of cutaneous squamous-cell carcinoma, survival free of melanoma progression, and response. Secondary end points were overall survival and pharmacokinetic activity. RESULTS: Dose-limiting toxic effects were infrequently observed in patients receiving combination therapy with 150 mg of dabrafenib and 2 mg of trametinib (combination 150/2). Cutaneous squamous-cell carcinoma was seen in 7% of patients receiving combination 150/2 and in 19% receiving monotherapy (P=0.09), whereas pyrexia was more common in the combination 150/2 group than in the monotherapy group (71% vs. 26%). Median progression-free survival in the combination 150/2 group was 9.4 months, as compared with 5.8 months in the monotherapy group (hazard ratio for progression or death, 0.39; 95% confidence interval, 0.25 to 0.62; P<0.001). The rate of complete or partial response with combination 150/2 therapy was 76%, as compared with 54% with monotherapy (P=0.03). CONCLUSIONS:Dabrafenib and trametinib were safely combined at full monotherapy doses. The rate of pyrexia was increased with combination therapy, whereas the rate of proliferative skin lesions was nonsignificantly reduced. Progression-free survival was significantly improved. (Funded by GlaxoSmithKline; ClinicalTrials.gov number, NCT01072175.).
RCT Entities:
BACKGROUND: Resistance to therapy with BRAF kinase inhibitors is associated with reactivation of the mitogen-activated protein kinase (MAPK) pathway. To address this problem, we conducted a phase 1 and 2 trial of combined treatment with dabrafenib, a selective BRAF inhibitor, and trametinib, a selective MAPK kinase (MEK) inhibitor. METHODS: In this open-label study involving 247 patients with metastatic melanoma and BRAF V600 mutations, we evaluated the pharmacokinetic activity and safety of oral dabrafenib (75 or 150 mg twice daily) and trametinib (1, 1.5, or 2 mg daily) in 85 patients and then randomly assigned 162 patients to receive combination therapy with dabrafenib (150 mg) plus trametinib (1 or 2 mg) or dabrafenib monotherapy. The primary end points were the incidence of cutaneous squamous-cell carcinoma, survival free of melanoma progression, and response. Secondary end points were overall survival and pharmacokinetic activity. RESULTS: Dose-limiting toxic effects were infrequently observed in patients receiving combination therapy with 150 mg of dabrafenib and 2 mg of trametinib (combination 150/2). Cutaneous squamous-cell carcinoma was seen in 7% of patients receiving combination 150/2 and in 19% receiving monotherapy (P=0.09), whereas pyrexia was more common in the combination 150/2 group than in the monotherapy group (71% vs. 26%). Median progression-free survival in the combination 150/2 group was 9.4 months, as compared with 5.8 months in the monotherapy group (hazard ratio for progression or death, 0.39; 95% confidence interval, 0.25 to 0.62; P<0.001). The rate of complete or partial response with combination 150/2 therapy was 76%, as compared with 54% with monotherapy (P=0.03). CONCLUSIONS:Dabrafenib and trametinib were safely combined at full monotherapy doses. The rate of pyrexia was increased with combination therapy, whereas the rate of proliferative skin lesions was nonsignificantly reduced. Progression-free survival was significantly improved. (Funded by GlaxoSmithKline; ClinicalTrials.gov number, NCT01072175.).
Authors: Gerald S Falchook; Karl D Lewis; Jeffrey R Infante; Michael S Gordon; Nicholas J Vogelzang; Douglas J DeMarini; Peng Sun; Christopher Moy; Stephen A Szabo; Lori T Roadcap; Vijay G R Peddareddigari; Peter F Lebowitz; Ngocdiep T Le; Howard A Burris; Wells A Messersmith; Peter J O'Dwyer; Kevin B Kim; Keith Flaherty; Johanna C Bendell; Rene Gonzalez; Razelle Kurzrock; Leslie A Fecher Journal: Lancet Oncol Date: 2012-07-16 Impact factor: 41.316
Authors: Keith T Flaherty; Igor Puzanov; Kevin B Kim; Antoni Ribas; Grant A McArthur; Jeffrey A Sosman; Peter J O'Dwyer; Richard J Lee; Joseph F Grippo; Keith Nolop; Paul B Chapman Journal: N Engl J Med Date: 2010-08-26 Impact factor: 91.245
Authors: M A Cobleigh; C L Vogel; D Tripathy; N J Robert; S Scholl; L Fehrenbacher; J M Wolter; V Paton; S Shak; G Lieberman; D J Slamon Journal: J Clin Oncol Date: 1999-09 Impact factor: 44.544
Authors: Georgia Hatzivassiliou; Kyung Song; Ivana Yen; Barbara J Brandhuber; Daniel J Anderson; Ryan Alvarado; Mary J C Ludlam; David Stokoe; Susan L Gloor; Guy Vigers; Tony Morales; Ignacio Aliagas; Bonnie Liu; Steve Sideris; Klaus P Hoeflich; Bijay S Jaiswal; Somasekar Seshagiri; Hartmut Koeppen; Marcia Belvin; Lori S Friedman; Shiva Malek Journal: Nature Date: 2010-02-03 Impact factor: 49.962
Authors: K H T Paraiso; I V Fedorenko; L P Cantini; A C Munko; M Hall; V K Sondak; J L Messina; K T Flaherty; K S M Smalley Journal: Br J Cancer Date: 2010-06-08 Impact factor: 7.640
Authors: Thomas J Lynch; Daphne W Bell; Raffaella Sordella; Sarada Gurubhagavatula; Ross A Okimoto; Brian W Brannigan; Patricia L Harris; Sara M Haserlat; Jeffrey G Supko; Frank G Haluska; David N Louis; David C Christiani; Jeff Settleman; Daniel A Haber Journal: N Engl J Med Date: 2004-04-29 Impact factor: 91.245
Authors: George D Demetri; Margaret von Mehren; Charles D Blanke; Annick D Van den Abbeele; Burton Eisenberg; Peter J Roberts; Michael C Heinrich; David A Tuveson; Samuel Singer; Milos Janicek; Jonathan A Fletcher; Stuart G Silverman; Sandra L Silberman; Renaud Capdeville; Beate Kiese; Bin Peng; Sasa Dimitrijevic; Brian J Druker; Christopher Corless; Christopher D M Fletcher; Heikki Joensuu Journal: N Engl J Med Date: 2002-08-15 Impact factor: 91.245
Authors: Caroline M Emery; Krishna G Vijayendran; Marie C Zipser; Allison M Sawyer; Lili Niu; Jessica J Kim; Charles Hatton; Rajiv Chopra; Patrick A Oberholzer; Maria B Karpova; Laura E MacConaill; Jianming Zhang; Nathanael S Gray; William R Sellers; Reinhard Dummer; Levi A Garraway Journal: Proc Natl Acad Sci U S A Date: 2009-11-13 Impact factor: 11.205
Authors: Alan P Venook; Maria E Arcila; Al B Benson; Donald A Berry; David Ross Camidge; Robert W Carlson; Toni K Choueiri; Valerie Guild; Gregory P Kalemkerian; Razelle Kurzrock; Christine M Lovly; Amy E McKee; Robert J Morgan; Anthony J Olszanski; Mary W Redman; Vered Stearns; Joan McClure; Marian L Birkeland Journal: J Natl Compr Canc Netw Date: 2014-11 Impact factor: 11.908
Authors: Anna E Vilgelm; Jeff S Pawlikowski; Yan Liu; Oriana E Hawkins; Tyler A Davis; Jessica Smith; Kevin P Weller; Linda W Horton; Colt M McClain; Gregory D Ayers; David C Turner; David C Essaka; Clinton F Stewart; Jeffrey A Sosman; Mark C Kelley; Jeffrey A Ecsedy; Jeffrey N Johnston; Ann Richmond Journal: Cancer Res Date: 2014-11-14 Impact factor: 12.701
Authors: M Corazzari; F Rapino; F Ciccosanti; P Giglio; M Antonioli; B Conti; G M Fimia; P E Lovat; M Piacentini Journal: Cell Death Differ Date: 2014-11-07 Impact factor: 15.828
Authors: Paul W Sperduto; Wen Jiang; Paul D Brown; Steve Braunstein; Penny Sneed; Daniel A Wattson; Helen A Shih; Ananta Bangdiwala; Ryan Shanley; Natalie A Lockney; Kathryn Beal; Emil Lou; Thomas Amatruda; William A Sperduto; John P Kirkpatrick; Norman Yeh; Laurie E Gaspar; Jason K Molitoris; Laura Masucci; David Roberge; James Yu; Veronica Chiang; Minesh Mehta Journal: Int J Radiat Oncol Biol Phys Date: 2017-03-29 Impact factor: 7.038
Authors: Omar Abdel-Wahab; Virginia M Klimek; Alisa A Gaskell; Agnes Viale; Donavan Cheng; Eunhee Kim; Raajit Rampal; Mark Bluth; James J Harding; Margaret K Callahan; Taha Merghoub; Michael F Berger; David B Solit; Neal Rosen; Ross L Levine; Paul B Chapman Journal: Cancer Discov Date: 2014-03-03 Impact factor: 39.397